MDL 72527 (dihydrochloride)
Based on 2 publication(s) in Google Scholar
MDL 72527 is a potent polyamine oxidase (PAO) inhibitor. MDL 72527 shows a lysosomotropic effect. MDL 72527 shows neuroprotective effects.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 98.0%
- CAS 番号: 93565-01-6
- 分子式: C12H22Cl2N2
- 分子量:265.22
-
保管条件:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
MedChemExpress(MCE)の使用を引用している文献 MDL 72527
More
生物活性
polyamine oxidase (PAO)[1]
MDL 72527 (300 µM; 24 h) shows evident morphological changes with the appearance of a large number of lysosomes and numerous cytoplasmic vacuoles in M14 WT cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:M14 cells
-
Concentration:300 µM
-
Incubation Time:24 h
-
Result:Showed no significant effect on cell survival of melanoma cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:250-300 g, Male spontaneously hypertensive rats (SHRs)[1]
-
Dosage:100 mg/kg
-
Administration:I.p.; after the induction of ischemia
-
Result:Significantly reduced meanarterial blood pressure, changed the brain edema formation from 85.7 ± 0.3 to 84.5 ± 0.9% in cortex and from 79.9 ± 1.7 to 78.4 ± 2.0% in subcortex (difference not significant), reduced ischemic injury volume by 22% in the cortex and 17% in the subcortex.
化学情報
-
CAS 番号 93565-01-6
-
性状 Solid
-
分子量 265.22
-
分子式 C12H22Cl2N2
-
Color White to off-white
-
SMILES
C=C=CCNCCCCNCC=C=C.[H]Cl.[H]Cl
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Nature
2026 Jul;655(8121):240-250. PMID: 42236947 -
Proc Natl Acad Sci U S A
Activation of polyamine catabolism promotes glutamine metabolism and creates a targetable vulnerability in lung cancer. [Abstract]2024 Mar 26;121(13):e2319429121. PMID: 38513095
溶剤 & 溶解度
DMSO : 12.5 mg/mL (47.13 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (4.71 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: Saline
Solubility: 50 mg/mL (188.52 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (271 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Doğan A, et al. Effects of MDL 72527, a specific inhibitor of polyamine oxidase, on brain edema, ischemic injury volume, and tissue polyamine levels in rats after temporary middle cerebral artery occlusion. J Neurochem. 1999 Feb;72(2):765-70. [Content Brief]
[2]. Agostinelli E, et al. Toxicity of enzymatic oxidation products of spermine to human melanoma cells (M14): sensitization by heat and MDL 72527. Biochim Biophys Acta. 2006 Oct;1763(10):1040-50. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.7705 mL | 18.8523 mL | 37.7045 mL | 94.2614 mL |
| 5 mM | 0.7541 mL | 3.7705 mL | 7.5409 mL | 18.8523 mL | |
| 10 mM | 0.3770 mL | 1.8852 mL | 3.7705 mL | 9.4261 mL | |
| 15 mM | 0.2514 mL | 1.2568 mL | 2.5136 mL | 6.2841 mL | |
| 20 mM | 0.1885 mL | 0.9426 mL | 1.8852 mL | 4.7131 mL | |
| 25 mM | 0.1508 mL | 0.7541 mL | 1.5082 mL | 3.7705 mL | |
| 30 mM | 0.1257 mL | 0.6284 mL | 1.2568 mL | 3.1420 mL | |
| 40 mM | 0.0943 mL | 0.4713 mL | 0.9426 mL | 2.3565 mL |